Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Ziprasidone

Catalog No: tcsc1071

Available Sizes

Size: 10mg

Size: 50mg

Specifications

CAS No:
146939-27-7

Formula:
$C_{21}H_{21}ClN_4OS$

Pathway:
GPCR/G Protein;Neuronal Signaling;Neuronal Signaling;GPCR/G Protein

Target:
Dopamine Receptor;Dopamine Receptor;5-HT Receptor;5-HT Receptor

Purity / Grade:
>98%

Solubility:
DMSO : 13.5 mg/mL (32.69 mM; Need ultrasonic)

Alternative Names:
CP-88059

Observed Molecular Weight:
412.94

Product Description

Ziprasidone(CP88059) is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity.

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

IC50 value:

Target: 5-HT receptor; Dopamine receptor

Ziprasidone possesses an in vitro 5-HT2A/dopamine D2 receptor affinity ratio higher than any clinically available antipsychotic agent. In vivo, ziprasidone antagonizes 5-HT2A receptor-induced head twitch with 6-fold higher potency than for blockade of d-amphetamine-induced hyperactivity, a measure of central dopamine D2 receptor antagonism. Ziprasidone also has high affinity for the 5-HT1A, 5-HT1D and 5-HT2C receptor subtypes, which may further enhance its therapeutic potential [1]. Ziprasidone sulfoxide and sulfone were the major metabolites in human serum. The affinities of the sulfoxide and sulfone metabolites for 5-HT2 and D2 receptors are low with respect to ziprasidone, and are thus unlikely to contribute to its antipsychotic effects [2]. Ziprasidone was associated with significant differential adverse effects relative to placebo in BPM, BPD, and schizophrenia with no significant difference in weight gain in all 3 groups. Self-reported somnolence was increased across the 3 conditions. Subjects with BPM were more vulnerable to EPS than those with BPD or schizophrenia [3].

Clinical indications: Bipolar I disorder; Bipolar disorder; Mania; Schizophrenia

FDA Approved Date: February 2001